Seasoned investment banking executive brings extensive finance, partnering and M&A experience to the role WATERTOWN, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise,

Results demonstrate XTreo ™ technology platform provides targeted and sustained dosing of anti-inflammatory medication Outcomes supported advancing into clinical development for LYRA’s first indication, Chronic Rhinosinusitis, with lead product candidate, LYR-210, currently poised to enter Phase 3

WATERTOWN, Mass. , Sept. 07, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics , Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other

WATERTOWN, Mass. , Aug. 17, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics , Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other

- Successful EOP2 FDA meeting for LYR-210 in CRS; Phase 3 program on track to begin around year-end 2021 - - Licensing agreement with LianBio for LYR-210 in Greater China and other Asian markets - - Positive topline results of LYR-210 PK study support 505(b)(2) NDA pathway - WATERTOWN, Mass. , Aug.

WATERTOWN, Mass. , July 26, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased

WATERTOWN, Mass. , July 12, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics , Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other

-- Results Support 505(b)(2) NDA Pathway for LYR-210 -- First U.S. Study of LYR-210 Enrolled Rapidly WATERTOWN, Mass. , June 30, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc . (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise,

Single primary endpoint defined as three cardinal symptoms at 24 weeks Company to host conference call at 5:00 PM ET today WATERTOWN, Mass. --(BUSINESS WIRE)--Jun. 8, 2021-- Lyra Therapeutics, Inc . (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to

Partnership opens expanded opportunity for LYR-210 to address chronic rhinosinusitis, a disease affecting approximately 88 million adults in China   WATERTOWN, Mass. & SHANGHAI & PRINCETON, N.J. --(BUSINESS WIRE)--Jun. 2, 2021-- Lyra Therapeutics, Inc.